Showing 1 - 20 results of 10,567 for search '(( brain ((step decrease) OR (teer decrease)) ) OR ( _ ((parp decrease) OR (we decrease)) ))', query time: 0.42s Refine Results
  1. 1

    Inotodiol decreases clone formation in HCC cells. by Yushuang Xing (20636685)

    Published 2025
    “…In addition, inotodiol showed to induce apoptosis, characterized by an increase in Bax expression, a decrease in Bcl-2, Bcl-XL and MCL1 expression, the initiation of cleaved PARP1 and cleaved caspase 3, and inhibition of the MAPK/ERK pathway. …”
  2. 2
  3. 3
  4. 4
  5. 5

    Overview of the WeARTolerance program. by Ana Beato (20489933)

    Published 2024
    “…This research evaluates the "WeARTolerance’’ arts-based program in reducing mental health stigma among diverse youths. …”
  6. 6

    Application of WeChat-based cognitive behavioural stress management for early-stage cervical cancer patients: a randomised controlled study by Qing Hao (566198)

    Published 2024
    “…<p>This randomised controlled study was aimed at investigating the effects of WeChat-based cognitive behavioural stress management (WB-CBSM) on the mental health of patients with early-stage cervical cancer treated with surgical resection.…”
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12

    PARP9 knockdown promotes apoptosis and DNA damage. by Yating Li (1819822)

    Published 2024
    “…(E) DNA damage in GC cells significantly increased post-PARP9 knockdown as determined by comet assay. (F) The anti-DNA damage capacity of GC cells decreased markedly following reduction of PARP9 expression. …”
  13. 13
  14. 14
  15. 15
  16. 16

    Data Sheet 1_Imaging-based assessment of response to olaparib in platinum-sensitive relapsed ovarian cancer patients.pdf by Maria Delgado-Ortet (8840702)

    Published 2025
    “…Background<p>High-grade serous carcinoma is a highly metastatic disease with a limited longterm disease control from systemic anti-cancer treatment, for which the radiological treatment response assessment metrics are imprecise. In this work, we developed noninvasive imagingbased measurements of spatial and longitudinal heterogeneity in a retrospective analysis of a phase 2 non-randomized study of germline BRCA1/BRCA2 mutated (gBRCAm) ovarian cancer patients treated with combination of PARP inhibitors (PARPi) and immune checkpoint inhibitors (ICIs).…”
  17. 17
  18. 18
  19. 19
  20. 20